Cholecalciferol (Egostar®). HTA ID: 22033

Assessment Status Rapid Review complete
HTA ID 22033
Drug Cholecalciferol
Brand Egostar®
Indication Prevention of vitamin D deficiency in adult patients with an identified risk, initial treatment of clinically relevant vitamin D deficiency, and as an adjunct to specific therapy for osteoporosis in patients with vitamin D deficiency or at risk of vitamin D insufficiency.
Assessment Process
Rapid review commissioned 11/05/2022
Rapid review completed 23/06/2022
Rapid review outcome A full HTA is not recommended. The NCPE recommends that Egostar® not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.